Noxopharm’s NOXCOVID trial achieves full enrolment
In Part 1 of the study, an 1800 milligram dose of Veyonda® was determined to be well tolerated in patients with compromised lung function. Continuing analysis of blood samples for biomarkers of CRS and severity of COVID-19 disease is underway in an Australian laboratory.
Noxopharm Ltd (ASX:NOX) has fully enrolled Part 2 of the NOXCOVID study looking into the potential of Veyonda® to block the cytokine release syndrome (CRS) or ‘cytokine storm’ and improve the outcomes in patients hospitalised with COVID-19.
Part 2 of the study proceeded on the basis of the positive safety findings of NOXCOVID Part 1, where the 1800 milligram dose was found to be well tolerated by patients with compromised lung function.
F-star Therapeutics, Inc.: Study Published in Nature Shows F-Star s STING Agonist SB 11285 Enhances Preclinical Efficacy of Radiation Therapy
SB 11285 is a Second Generation STING Agonist Delivered Intravenously
CAMBRIDGE, United Kingdom and CAMBRIDGE, Mass., April 19, 2021. The study entitled STING enhances cell death through regulation of reactive oxygen species and DNA damage demonstrates that systemic administration of a STING agonist in combination with radiation in a preclinical model enhances local control in Head and Neck Squamous Cell Carcinoma (HNSCC) and suggests that STING expression in the tumor is required for maximal therapeutic benefit. The studies described in this paper demonstrate that systemic administration of SB 11285, a novel STING agonist, in combination with radiation, enhances the antitumor effects in animal models of HNSCC. Furthermore, STING expression in the tumor can be used as a predictive biomarker and a combination of radiation with SB 11285 dem
Press release content from Globe Newswire. The AP news staff was not involved in its creation.
Study Published in Nature Shows F-Star’s STING Agonist SB 11285 Enhances Preclinical Efficacy .
F-star Therapeutics, Inc.April 19, 2021 GMT
SB 11285 in Combination with Radiation is More Effective than Either as Monotherapy in a Murine Tumor Model
SB 11285 is a Second Generation STING Agonist Delivered Intravenously
CAMBRIDGE, United Kingdom and CAMBRIDGE, Mass., April 19, 2021 (GLOBE NEWSWIRE) F-star Therapeutics, Inc. (NASDAQ: FSTX), a clinical-stage biopharmaceutical company dedicated to developing next generation bispecific immunotherapies to transform the lives of patients with cancer, today announced the publication of a new study, conducted by Yale University and F-star, of its second generation STING agonist, SB 11285, in the current issue of
Share this article
Share this article
ResearchAndMarkets.com s offering.
The STING Pathway Targeting Therapeutics and Technologies report features an extensive study of the current market landscape and future potential of these therapeutics and affiliated technologies, over the next decade. This study focuses specifically on small molecule STING modulators. The report features an in-depth analysis, highlighting the diverse capabilities of stakeholders engaged in this domain.
In recent years, promising insights from research on the cytosolic DNA sensing (cGAS -STING) pathway has caused a lot of enthusiasm within medical science community. Basically, the STING pathway offers an alternative approach to harnessing the immune system, in order to pharmacologically treat a number of clinical conditions, including oncological and autoimmune disorders. The aforementioned therapeutic benefits can be achieved using modulators of the STING/cGAS-pathway. Over the years, a number of such mo
Press release content from Business Wire. The AP news staff was not involved in its creation.
Silicon Therapeutics Announces Members of Scientific Advisory Board
December 10, 2020 GMT
BOSTON (BUSINESS WIRE) Dec 10, 2020
Silicon Therapeutics, a privately-held, integrated therapeutics company with a pioneering drug discovery platform based on physics-driven molecular simulations, today announced the members of the Silicon Therapeutics scientific advisory board (SAB), which include Dr. Elliot L. Chaikof, Dr. Timothy P. Heffernan, Dr. Sun Hur, Dr. Pasi A. Jänne and Dr. Lijun Sun.
ADVERTISEMENT
Silicon Therapeutics Scientific Advisory Board Member Elliot L. Chaikof, M.D., Ph.D.
The Silicon Therapeutics SAB is comprised of experts in biophysics, medicinal chemistry, translational medicine and research and development (R&D) in oncology and immunology. These experts will serve as a strategic resource for Silicon Therapeutics to provide scientific review and high-level advice about t